20:49 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; pulmonary

INDICATION: Asthma; pulmonary fibrosis Mouse studies suggest an inhaled prodrug of a PI3K inhibitor could help treat asthma and pulmonary fibrosis. In mouse models of acute allergic asthma and chronic asthma, inhalation of a methylbenzoate-based...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
21:10 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
22:23 , Sep 14, 2017 |  BC Extra  |  Company News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
20:44 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Bayer reports Phase II data for PI3K inhibitor copanlisib in DLBCL

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 67 patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who received ≥1 prior therapy showing that 60 mg IV copanlisib (BAY...
16:00 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2 , TACC1 , ZAK , ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast...
00:20 , May 19, 2017 |  BC Week In Review  |  Clinical News

Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer expects a decision within six months....
19:31 , May 17, 2017 |  BC Extra  |  Company News

Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer did not respond to an inquiry...
19:41 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Copanlisib: Ph II CHRONOS-1 data

Bayer said the open-label, international Phase II CHRONOS-1 trial in 142 patients with relapsed or refractory indolent B cell NHL who received ≥2 prior therapies showed that 60 mg IV copanlisib on days 1, 8...